Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination Skip to content The CRC Digest Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84
RAS mutation linked to early progression in liver metastases conversion therapy Skip to content The CRC Digest RAS mutation linked to early progression in liver metastases conversion therapy Retrospective study of 194 patients with initially unresectable, pMMR colorectal liver metastases found that RAS mutation status was associated with early progression or recurrence after conversion therapy. (Front Surg) This content is informational
Treatment variation impacts survival in early-onset metastatic CRC Skip to content The CRC Digest Treatment variation impacts survival in early-onset metastatic CRC A retrospective analysis of patients diagnosed with stage IV CRC between 2004-2022 found that treatment patterns and outcomes varied by age, with patients under 50 showing different utilization of chemotherapy, immunotherapy, and metastasis resection compared to
CRC Research Finding Skip to content The CRC Digest ▸ Meta-Analysis Confirms Targeted Therapy Benefits for Colorectal Cancer Liver Metastases A systematic review and meta-analysis evaluated targeted therapy in colorectal cancer liver metastases, examining overall survival, progression-free survival, objective response rate, and conversion to resection. The analysis provides comprehensive evidence on the role of